Aspira Pathlab & Diagnostics Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Mar 2021

1. The above financial results of the Company were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respectivemeetings held on 05.06.2021. The statutory auditors of the Company have expressed an unmodified opinion thereon.2. The financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) as notified by the Ministry of Corporate Affairsand prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of theSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.3. The figures for the quarter ended 31 March 2021 and 31 March 2020 are the balancing figures between audited figures in respect of full financial year and thepublished year to date unaudited figures up to the third quarter ended 31 December 2020 and 31 December 2019 respectively, which was subjected to limitedreview.4. During the quarter, pursuant to approval by the shareholders in its general meeting held on 29 September 2020, on 07 Janunary 2021 the Company has allotted10,00,000 equity shares of Rs. 10 each at an issue price of Rs. 30 each (including premium of Rs. 20 each) aggregating to Rs. 300 Lakhs to strategic investors namelyGlorious Holdings Private Limited and Vincent Commercial,not forming part of promoter group, on preferential basis.5. The Board of Directors of the Company, which has been identified as being the Chief operating decision maker, evaluates the Company's performance allocatesresources based on the analysis of the various performance indicators of the Company as a single unit.Therefore, there is no reportable segment of the Company inaccordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.6. During Q1 of FY 2020-21,following Government directives on lockdown the Company operated at sub optimal levels. While most of the economic activities were at halt during the lockdown period, the healthcare sector continued its operations under the Essentials Commodities Act. The Company resumed full operationsfrom Q2'2020-21 onwards. Accordingly, the Company's operations continued to service its customers across channels.The Company is well equipped to adapt to the evolving business environment and has scaled up its operations to fulfil the needs of its customers.7. The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post- employment benefits received Presidential assent in

September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The

Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.

8. The previous period figures have been regrouped/reclassified wherever required.